AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03252600
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01367080
Drug: DWETR10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline hydrochloride 10mg(DWETR10) single dose
Trial: NCT01367080
Drug: DWETR25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline hydrochloride 25mg(DWETR25) single dose
Trial: NCT01820624
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01944839
Drug: E10030
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02646137
Drug: Transarterial chemoembolization (TACE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
Trial: NCT03744091
Drug: P1
RxNorm normalized name: P1E1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg or 20 mg of THC:THCa
Trial: NCT00924170
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days 1-3:~Patients 1-7, 10 -14, and \>18:250 mg/m\^2/day Patients 8 - 9:300 mg/m\^2/day Patients 15-17:200 mg/m\^2/day
Trial: NCT02025556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously Administered Placebo (Vehicle) Monthly x 3
Trial: NCT02620163
Drug: YH22162 40/5/12.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02620163
Drug: YH22162 80/5/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02620163
Drug: YH22162 40/5/12.5 mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02620163
Drug: YH22162 80/5/25 mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00394992
Drug: oxaliplatin+capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
Trial: NCT02282826
Drug: GZ402668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution Route of administration: intravenous
Trial: NCT02282826
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution Route of administration: intravenous
Trial: NCT02282826
Drug: GZ402668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Trial: NCT02282826
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Trial: NCT00812760
Drug: levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 tablet of 200 mg levodopa plus 50 mg benserazide
Trial: NCT04138979
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: First use of chemotherapy after breast cancer
Trial: NCT00456144
Drug: Gonadotropin Releasing Hormone Agonist Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given either for 24 months and 6 months
Trial: NCT02420782
Drug: ASP6282
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02420782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01325220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tid
Trial: NCT04531631
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00042029
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02694718
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m\^2 bid orally on Days 1-14, and at a dose of 825mg/m\^2 bid on Days 22-35 and 43-56.
Trial: NCT01551940
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.
Trial: NCT04160416
Drug: Capecitabine-Oxaliplatin-Irinotecan Combination
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; CET: 500 mg/sq.m (d.i.v.) D1; Administered every 2 weeks.
Trial: NCT00266461
Drug: Daikenchuto Extract Granules (TU-100)
RxNorm normalized name: mustard pollen extract 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03458598
Drug: Patient controlled opioid analgesia (PCA)
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.
Trial: NCT02573701
Drug: Guideline treatment (Risperidone, administered orally)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group
Trial: NCT02573701
Drug: Treatment as Usual (any other antipsychotic)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive the Treatment as Usual (atypical antipsychotic) plus Behavioral Intervention: psychosocial treatment assigned by clinician.
Trial: NCT00384111
Drug: Zevalin Therapeutic Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
Trial: NCT00384111
Drug: R-CVP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard R-CVP
Trial: NCT03657966
Drug: Standard of Care Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa
Trial: NCT00995488
Drug: ABI-007 (Abraxane®)
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
Trial: NCT01501084
Drug: Normal saline .2cc subcutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile saline injection
Trial: NCT03419975
Drug: TJO-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
Trial: NCT05958693
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)
Trial: NCT03345953
Drug: BP 1.4979
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double blind versus placebo
Trial: NCT03345953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double blind versus placebo
Trial: NCT00684216
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg, BID, PO, QD until progression of disease
Trial: NCT01289990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 10773 low dose
Trial: NCT01289990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 10773 high dose
Trial: NCT01289990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Sitagliptin
Trial: NCT01181401
Drug: TPF induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
Trial: NCT01181401
Drug: TPF experimental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
Trial: NCT03945175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the two-week, placebo lead-in, all patients will receive 12.5mg of placebo at Visit 1 and Visit 2.
Trial: NCT00168987
Drug: oral nutritional supplement rich in eicosapentanoic acid
RxNorm normalized name: docosahexaenoate / eicosapentaenoate / omega-3 acid ethyl esters (USP) Oral Capsule [Ocean Blue Nutritionals Omega-3 1450]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04493125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01969539
Drug: Combivent Respimat via tee adapter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
Trial: NCT01969539
Drug: Combivent Respimat via ventilator adapter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via ventilator adapter
Trial: NCT04022161
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT02547883
Drug: Cessation of statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention evaluated is the cessation of statin
Trial: NCT01649245
Drug: Reiferon retard
RxNorm normalized name: Uniferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is \>75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
Trial: NCT01514370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received placebo matched to curcumin orally twice a day for 24 months.
Trial: NCT00928135
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
Trial: NCT00624702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01426789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to secukinumab I.V.
Trial: NCT02200614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo 2 tablets twice daily with food.
Trial: NCT04616742
Drug: [14C]SHR6390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive single dose of orally \[14C\]SHR6390 on Day 1.
Trial: NCT01739855
Drug: Calciferol, calcium carbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00278408
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00278408
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02456480
Drug: CLS001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gel
Trial: NCT02456480
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gel
Trial: NCT02284672
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01307020
Drug: Dexketoprofen Trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen Trometamol low dose, oral film-coated table, once
Trial: NCT01307020
Drug: Dexketoprofen Trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen Trometamol high dose, oral film-coated table, once
Trial: NCT01307020
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400 mg, oral film-coated table, once
Trial: NCT01307020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral film-coated table, once
Trial: NCT01307020
Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride
RxNorm normalized name: dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
Trial: NCT01307020
Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride
RxNorm normalized name: dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
Trial: NCT01307020
Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride
RxNorm normalized name: dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
Trial: NCT01307020
Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride
RxNorm normalized name: dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
Trial: NCT03343418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 100 milliliters (mL) 0.9% saline (SF0,9%). After 0.9% saline infusion, bleeding treatment will follow the predefined standardized treatment regimen.
Trial: NCT03911843
Drug: omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 22/64 T1D children
Trial: NCT02975583
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet daily
Trial: NCT00604214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride, intravenous, 96 hours
Trial: NCT00327652
Drug: CRS-100
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Live-attenuated Listeria monocytogenes
Trial: NCT00402207
Drug: extrafine HFA-beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02630004
Drug: Melatonin oral gel 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02630004
Drug: Placebo oral gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00739622
Drug: TMC278
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01531062
Drug: Nigella sative
RxNorm normalized name: Nigella sativa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
Trial: NCT00399919
Drug: PLC
RxNorm normalized name: Drive Cane Tip Rplc 3/4 Blk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 grams/day for six months
Trial: NCT01066676
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg, powder for oral suspension, daily dose 1600mg
Trial: NCT03120520
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00817479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo saline
Trial: NCT01216371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
Trial: NCT02829944
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02829944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03798899
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03997968
Drug: CYT-0851 in combination with capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine
Trial: NCT01138943
Drug: Synthodont
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml, tree times/day for 07 days~Arm: Chlorhexidine alcohol-base mouthrinse
Trial: NCT02345408
Drug: CCX872-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets (oral administration)
Trial: NCT02328547
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules prepared by OpenBiome, Medford, MA
Trial: NCT00441207
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delivered via IV Infusion.
Trial: NCT04302025
Drug: SBRT
RxNorm normalized name: Stereotactic Body Radiation Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive SBRT given concurrently starting with the first dose of atezolizumab
Trial: NCT01472315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills were taken in same way as active comparator
Trial: NCT01925131
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00900887
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week
Trial: NCT00900887
Drug: Nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week
Trial: NCT00900887
Drug: Polietilenglicol 400, propilenglicol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml~dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week
Trial: NCT04302025
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician
Trial: NCT02085005
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT01461369
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 35 mg bid Capsules
Trial: NCT01461369
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 35 mg tid Capsules
Trial: NCT02378467
Drug: 7% Hypertonic Saline (HS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
Trial: NCT02228369
Drug: AZD3759
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined
Trial: NCT02228369
Drug: AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9291 160mg once daily
Trial: NCT00006103
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006103
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03521102
Drug: Acetaminophen 1000mg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg of IV acetaminophen in 100ml of normal saline, administered as an intravenous drip over 10 minutes + 2ml of normal saline, administered as a slow intravenous push
Trial: NCT00053599
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01226615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo capsules taken once a day for four months.
Trial: NCT02868814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03106766
Drug: Acne cream 2X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application of facial acne cream 2X after facial cleansing